The second trials for GDNF were stopped by Amgen after the overview of the GDNF trials was given to Roger Pearlmutter, an executive at Amgen, who announced that there were not enough surgical theaters to place the catheters and the company could not make enough money with the current methods of administration.
Monkeys in the Middle – A Book | Julie's Attic